Objectives -To assess the feasibility of a randomised trial ofovarian cancer screening by vaginal ultrasonography. Setting -A population based study, recruiting a random sample of the female population aged 46 to 65 years living in Copenhagen, Denmark. Design -Randomised controlled trial allocating 50% to the study group having vaginal ultrasonography, and 50% to the control group having no examination. (a) Acceptability of the study was evaluated by the proportion ofeligible women willing to participate in the study. (b) The false positive rate was evaluated as the proportion of women without ovarian cancer referred for an operation because of abnormal ovaries detected by ultrasonography. Results -950 (64'3%) of the 1477 eligible women participated in the study. At the first scan abnormal ovaries were detected in 54 of 435 women (12%), significantly more frequently among younger women. Nine women were referred for an operation because of abnonnal findings in the ovaries, giving a false positive rate of 2%. Ovarian size and morphology found at operation correspoeded with those at ultrasonography; none of them was malignant. Conclusions -A randomised controlled trial of ovarian cancer screening using vaginal ultrasonography seems acceptable in the general population. The rate of abnormal ovaries at ultrasonography with the cut offs used in this study was quite high. Such a study is, therefore, feasible, but it is proposed that it is carried out in an older age group (50-64 years) and that the cut offs used for ovarian size and morphology are re-evaluated. Second line tests, such as colour Doppler flow, should be considered in order to reduce the false positive rate. (Journal of Medical Screening 1994;1:215-219) Ovarian cancer is now the gynaecological cancer with the highest mortality, and it has increased from six to 10 per 100 000 women over the past 30 years in Denmark.' The length of survival after diagnosis is closely related to stage of disease at the time of diagnosis: if diagnosed in FIGO stage III or IV the five year survival rate is less than 25%, whereas it is more than 90% for stage I -that is, when the disease is confined to the ovary.' If it were possible to diagnose ovarian cancers before they spread the survival rate should therefore increase.
Ovarian cancer is now the gynaecological cancer with the highest mortality, and it has increased from six to 10 per 100 000 women over the past 30 years in Denmark. ' The length of survival after diagnosis is closely related to stage of disease at the time of diagnosis: if diagnosed in FIGO stage III or IV the five year survival rate is less than 25%, whereas it is more than 90% for stage I -that is, when the disease is confined to the ovary.' If it were possible to diagnose ovarian cancers before they spread the survival rate should therefore increase.
Previous attempts at early diagnosis of this disease have been unsuccessful. During the last decade, however, a new screening testultrasonography -has shown promise." Although it has not yet been proved, an ovarian cancer might be expected to change the size or morphology of the ovary before spreading outside the capsule, and these changes might be detected by ultrasonography. Even if ultrasonography were able to diagnose ovarian cancer, the question is, however, whether the mortality from the disease would be reduced.
The potential of this new technique should be properly evaluated in a randomised controlled trial before implementation. As such a trial would require the participation of a very large number of women we carried out a pilot study to evaluate its feasibility.
The purposes of our study were to determine (a) the proportion of women willing to participate in a randomised controlled trial of ultrasonography in the detection of ovarian cancer and (b) the false positive rate of the examination -that is, the proportion of women referred for an operation who did not have an ovarian cancer.
Material and methods A random sample of 1557 women aged 46 to 65 years was obtained from the Central Person's Registry. These women comprised 4% of the age group living in the city of Copenhagen on 11 November 1990. To exclude those women already diagnosed as having ovarian cancer the names and dates of birth of these women were cross checked with the Danish Cancer Registry.
An invitation (signed by the investigators) to participate in a randomised trial of ovarian cancer screening, a questionnaire, and a prepaid envelope were sent to those women who had not had ovarian cancer previously. Those women returning the questionnaire supplied background information about gynaecological and obstetric history, hormone replacement therapy, smoking, and dietary habits. One reminder was sent to women who had not returned the questionnaire after one month.
Women were classified as postmenopausal if the last menstrual period preceded the date of the ultrasound scan by more than 12 months. Women were classified as receiving hormone replacement therapy (HRT), irrespective of their age and previous menopausal state, when they were taking HRT. This was also the case for those women who had had a hysterectomy. • HRT = hormone replacement therapy. Women who had had a hysterectomy and were not receiving HRT were classified as hysterectomised until the age of 55 years; thereafter they were classified as postmenopausal. Women wishing to participate were randomly allocated to the study (50%) or to the control group (50%). Women in the control group were not examined. Women in the study group had a vaginal ultrasonographic examination carried out by a specially trained nurse using a Bruel and Kja:r sector scanner with a 7 mHz vaginal probe. The ultrasound scan included measurement and examination of the uterus and endometrium, measurement of both ovaries in three planes, and evaluation of their morphology. No action was taken solely on the • Abnormal ovarian volume, morphology, or outline at first scan. • Abnormal ovarian volume, morphology, or outline at first scan. basis of endometrial thickness. When the nurse could not see both ovaries a doctor specialised in gynaecological ultrasonography (FRD took over the examination. The findings were subsequently classified as normal, even if the ovaries had not been seen, when a doctor had performed the examination and found no other sign of pelvic tumour. Ovarian volume was calculated by the ellipsoid formula (width x height x thickness x 0'523). 3 The result of a scan was regarded as positive if any of the following were present: • ovarian volume above 14 ml in premenopausal women or 8 ml in postmenopausal women, those having had a hysterectomy, and those receiving HRT • ovarian outline irregular • ovarian morphology either hyperechogenic or hypoechogenic. Women with a normal scan (screen negative) were informed that they would be recalled for screening after three years if funding of the study continued. Women with an abnormal scan (screen positive) had a review scan after three to eight weeks to exclude transient cyclical changes. If the review scan was still positive the woman was referred for laparoscopy or laparotomy. Women with a unilocular cyst less than 6 em in diameter, with smooth walls and no septations, were res canned only at three to six month intervals. If the cyst was still present after two years an operation was recommended. 
Results
Of the cohort of 1557 women, five had previously had ovarian cancer, and thus questionnaires were sent out to 1552 women. Seventy five could not participate in the study: 57 because they had undergone bilateral oophorectomy and 18 for other reasons (mental handicap (eight), moved away from Copenhagen (four), could not answer the questionnaire (three), recent operation for another cancer (two), and other disease (one)). The study group therefore comprised 1477 women (figure).
Nine hundred and fifty women (64'3%) wished to participate in the study, and were randomly allocated to the study group (474) or the control group (476). Four hundred and thirty six women attended the clinic, and of these, 435 had an ultrasound scan performed; one woman had joined the study, although she had previously undergone bilateral oophorectomy. Thirty eight women did not keep their appointment, giving a nonattendance rate of 8%.
ULTRASONOGRAPHY
Ovarian size was correlated with age and menopausal state (table 1) . In 381 women the ovaries were normal and had a normal morphology. One or both ovaries were not detected in 19 women (4%); the youngest of these women was 56 years.
In 54 women (12%) the ovaries were abnormal at the time of the first scan, but at follow up review scans 21 of them had normal ovaries at the first, eight at the second, and five at the third. Eleven women were followed up with control scans for more than one year. The screen positive rate at the initial scan was thus 12%, reducing to 8% after a review scan three to eight weeks later.
Nine women (2%) were advised to have surgery, and all had an operation. Three women were referred directly for an operation, three after one review scan, two after five scans, and one woman agreed to have an operation only after eight review scans. Ovarian size and morphology at operation corresponded with those determined by ultrasonography (table 2), except for one woman (No 542). In this last case ultrasonography detected a multicystic ovary with a diameter of 6·1 ern, whereas at operation a cyst of the same size was found on the fundus of the uterus, and several small cysts were found on the peritoneum in the pouch of Douglas.
Screen positive women were younger (median 51 years) than the whole study group (median 54 years) (P<0'05) (table 3), while there was no difference in menopausal state (table 4) .
Five other women had abnormal findings outside the ovaries (table 5) .
Discussion
In this study of 435 asymptomatic women aged 46 to 65 years vaginal ultrasonography detected an ovary with abnormal volume, outline, or morphology in 54 (12%). This rate is higher than expected as only one third of the women were premenopausal or perimenopausal. Postmenopausal ovaries have previously been believed to be quiescent, but recent studies suggest that they are much more dynamic than previously believed. In an American study of 184 asymptomatic postmenopausal women ovarian cysts were detected at the first examination in 32 (17%). 4 In our study group a third of the women recruited were receiving HRT. The distinction between the premenopausal and postmenopausal state is therefore uncertain in some of those cases. More than one third of the abnormal ovaries were found among the premenopausal women. The rate of abnormal ovaries detected could be reduced, therefore, by excluding premenopausal women from the study, but it is difficult to select women by menopausal state. Selection by age is evidently much more feasible. Almost half of the abnormal ovaries detected were found among women under the age of 50 years and less than a quarter in women aged 55 years or more.
In the Reading study" the false positive rate was 2'9%, when defined as the proportion of. women referred for a colour Doppler examination after two positive scans. This rate would have been 7'5% in our study.
The false positive rate of a vaginal ultrasound scan was 2%, when defined as the proportion of women referred for an operation who did not have an ovarian cancer. Apart from one case, the size and the morphology of the operative findings corresponded with those obtained by ultrasonic imaging. Our study thus confirms that ultrasonography has a high predictive value for the size and morphology of ovarian lesions.67
The size and morphology of the ovarian tumours detected in this study would generally indicate that an operation was necessary. A cystadenoma was found in six of the nine women who were operated on. Such tumours may transform to cystadenocarcinomas," and therefore removal of these benign tumours may prevent some cases of ovarian cancer. Of the other three women, two had multicystic ovaries indicating an operation, whereas one had a unilocular cyst. Unilocular cysts are seldom malignant and most disappear spontaneously," 7 9 The false positive rate of 2% was judged to be high. One might argue that the term false positive rate is inappropriate as most of these women had an ovarian tumour, though a benign one. A better term may be intervention rate; but even so, a 2% intervention rate seems high considering the low incidence of ovarian cancer (less than 1 per 1000). This means that 20 operations would be required to detect one case of ovarian cancer and perhaps prevent some other cases. The question must be asked as to whether this is acceptable to the participating women and to the health authorities.
Tabor, Jensen, Bock, HlIgdall
The proportion of women referred for an operation in our study is comparable with that found in the other two prospective population studies using ultrasonography to detect ovarian cancer. Firstly, in the United States van Nagell and coworkers examined 1300 women by vaginal ultrasonography and found two cases of ovarian cancer among the 27 women (2'1 %) referred for an operation." Secondly, in the British study 5479 women had abdominal ultrasonography on three occasions at 18 month intervals, and five cases of ovarian cancer were detected." The overall false positive rate -that is, referral for an operation due to an abnormal scan in women without ovarian cancer, was 2·3%. Interestingly, the 10 primary ovarian cancers detected by ultrasound screening so far -in asymptomatic women 9 1O or in family studies" -have been in stage I.
To reduce the false positive rate a second line test could be introduced. It has been suggested that colour Doppler flow may distinguish between benign and malignant masses." In two recent studies of symptomatic women,':' 14 however, the detection rate was the same or higher when ultrasonic morphology was used rather than any of the Doppler variables, whereas the false positive rate was reduced when a colour Doppler examination was used to differentiate between benign and malignant masses. If colour Doppler flow is used as a second line test the highest peak systolic velocity may be the best discriminating variable.'? The value of tumour markers, especially CA 125, has also been investigated in screening for ovarian cancer. A large study from London has shown that the predictive value of CA 125 is low when screening postmenopausal women." The malignancies detected by tumour markers were in advanced stages in seven of the 11 cases found during a screening of 22 000 women. In a Swedish population based study of 5550 healthy women screened by CA 125, four of the ovarian cancers detected were in stages I or II, while two were in more advanced stages. 16 We do not believe that there is sufficient evidence at present to suggest that tumour markers should be used as the primary screening test for ovarian cancer.
We recruited women from the general population by letter. The 64% participation rate is comparable with that found in other randomised trials 17 18 and in screening studies for other cancers. 18 19 The participation rate may increase if all women of a specified age group in a defined area are invited, or different approaches for invitation are used. In the Reading study" the uptake was 82%, somewhat higher than in our study. This is not surprising as recruitment methods were different -the Reading study recruiting from a breast cancer screening clinic, whereas our study group comprised a population based sample receiving a written invitation.
In conclusion, it seems possible that a randomised trial of ovarian cancer screening could be performed to evaluate whether early detection of ovarian cancer increases the length of survival. A 12% screen positive rate at ultrasound scan and a 2% operation rate seem unacceptably high, however. Before starting such a randomised trial it will therefore be necessary to consider carefully which age group should be screened, and to revise the definition of an abnormal ovary.
